Insider Selling: Insmed Incorporated (NASDAQ:INSM) COO Sells 1,457 Shares of Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) COO Roger Adsett sold 1,457 shares of the company's stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04. Following the completion of the transaction, the chief operating officer now owns 146,082 shares in the company, valued at approximately $10,038,755.04. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Price Performance

Shares of INSM traded up $2.55 during trading hours on Thursday, reaching $72.75. The stock had a trading volume of 2,264,024 shares, compared to its average volume of 2,139,833. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The stock has a market capitalization of $13.01 billion, a PE ratio of -13.11 and a beta of 1.12. The company's 50-day moving average is $71.18 and its two-hundred day moving average is $72.47.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. The business's revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the prior year, the business posted ($1.10) EPS. Research analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of recent research reports. Bank of America increased their target price on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. increased their price objective on Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research report on Friday, November 22nd. HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. Finally, Truist Financial reaffirmed a "buy" rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $83.67.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. V Square Quantitative Management LLC acquired a new position in shares of Insmed in the 3rd quarter worth approximately $30,000. GAMMA Investing LLC lifted its holdings in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 224 shares during the period. Exchange Traded Concepts LLC boosted its position in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock valued at $55,000 after acquiring an additional 627 shares during the last quarter. JCIC Asset Management Inc. acquired a new stake in Insmed during the 3rd quarter worth about $133,000. Finally, Quantbot Technologies LP bought a new position in shares of Insmed in the 3rd quarter worth about $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.